Concepedia

Edmund P. Harrigan

EP

Statistics

Publications

14

Citations

1.7K

H-Index

11

Active since

1994

Affiliations

Pfizer (United States)(Current)

Massachusetts General Hospital

Sunovion (United States)

PRA Health Sciences

University of Cincinnati Medical Center

Edmund P. Harrigan is an author at Pfizer (United States) specializing in psychopharmacology, medicine, and antipsychotic pharmacotherapy.

Publications per year

1994–2004

14

Publications

14

A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition

Edmund P. Harrigan, Jeffrey Miceli, Richard Anziano et al. · Journal of Clinical Psychopharmacology · 2004 · 358 citations

, , +14

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

P E Keck, Alan Buffenstein, James M. Ferguson et al. · Psychopharmacology · 1998 · 268 citations

, , +14

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

Kevin R. Fontaine, Moonseong Heo, Edmund P. Harrigan et al. · Psychiatry Research · 2001 · 230 citations

, , +12

Intramuscular Ziprasidone, 2 mg Versus 10 mg, in the Short-Term Management of Agitated Psychotic Patients

Michael D. Lesem, John Zajecka, R.H. Swift et al. · The Journal of Clinical Psychiatry · 2001 · 220 citations

, , +17

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

David G. Daniel, Steven G. Potkin, Karen R. Reeves et al. · Psychopharmacology · 2001 · 174 citations

, , +14

1–5 of 14